Association between differentiated HIV care delivery model and low-level viremia among people living with HIV in Rwanda

被引:0
|
作者
Sebeza, Jackson [1 ,2 ]
Mbwana, Mariam. S. [2 ]
Ramadhani, Habib. O. [3 ]
Ally, Zuhura M. [4 ]
Lascko, Taylor [3 ]
Memiah, Peter [5 ]
Tuyishime, Simeon [6 ]
Rwibasira, Galican [6 ]
机构
[1] Univ Rwanda, Coll Med & Hlth Sci, Sch Publ Hlth, POB 3286, St Name KG 11 Ave Gasabo Kigali, Kigali, Rwanda
[2] Primary Hlth Care Inst, Iringa, Tanzania
[3] Univ Maryland, Inst Human Virol, Sch Med, Baltimore, MD USA
[4] Dist Hosp, Tanga, Tanzania
[5] Univ Maryland, Grad Sch, Baltimore, MD USA
[6] Minist Hlth, Rwanda Biomed Ctr, Kigali, Rwanda
来源
AIDS RESEARCH AND THERAPY | 2024年 / 21卷 / 01期
关键词
Differentiated care delivery model; Low-level viremia; Viral load suppression; People living with HIV; Antiretroviral; ANTIRETROVIRAL THERAPY; TREATMENT OUTCOMES; INITIATION; ADULTS; ART;
D O I
10.1186/s12981-024-00650-3
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
BackgroundLow-level viremia (LLV) (HIV-RNA 51-999 copies/mL) is associated with increased risk of non viral load suppression (HIV-RNA >= 1000 copies/mL). We assessed the association between differentiated service delivery model (DSDM) and LLV among people living with HIV (PLHIV) in Rwanda.MethodsWe conducted a retrospective cohort analysis using routinely collected data of adults living with HIV from 28-healthcare facilities in Rwanda before and after the introduction of DSDM. Under DSDM, PLHIV initiated treatment within seven days of HIV diagnosis and medication pick-up up to six months for those with sustained viral load suppression suppression. Proportions of LLV at 6,12 and 18 months were quantified. Multivariable log binomial regression models were used to assess the effect of DSDM on LLV. To handle missing data, multiple imputations was performed.ResultsOf 976 people living with HIV, 645(66.0%) were female and 463(47.4%) initiated treatment during DSDM. The median age was 37 (interquartile range: 32-43) years. LLV was 7.4%, 6.6% and 5.4%, at 6,12 and 18 months, respectively. Compared to those who initiated treatment before DSDM, starting treatment during DSDM increased six-month LLV [adjusted risk ratio (aRR) = 2.8: 95%CI (1.15-6.91)] but not at 12 [aRR = 2.3: 95%CI (0.93-5.75)] and 18 months [aRR = 0.3: 95%CI (0.09-1.20)]. Using imputed datasets, the association between DSDM and LLV persisted.ConclusionsDSDM was associated with increased risk of LLV at 6-months. possibly due to the minimal amount of time PLHIV had in pondering and accepting the HIV diagnosis. Continued support is needed among people receiving early antiretroviral therapy initiation to prevent development of LLV.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy
    Chen, Guan-Jhou
    Sun, Hsin-Yun
    Chang, Sui-Yuan
    Cheng, Aristine
    Huang, Yu-Shan
    Huang, Sung-Hsi
    Huang, Yi-Chia
    Su, Yi-Ching
    Liu, Wen-Chun
    Hung, Chien-Ching
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 105 : 147 - 151
  • [22] HIV-1 persistent viremia is frequently followed by episodes of low-level viremia
    Widera, Marek
    Dirks, Miriam
    Bleekmann, Barbara
    Jablonka, Robert
    Daeumer, Martin
    Walter, Hauke
    Ehret, Robert
    Verheyen, Jens
    Esser, Stefan
    MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2017, 206 (03) : 203 - 215
  • [23] HIV-1 persistent viremia is frequently followed by episodes of low-level viremia
    Marek Widera
    Miriam Dirks
    Barbara Bleekmann
    Robert Jablonka
    Martin Däumer
    Hauke Walter
    Robert Ehret
    Jens Verheyen
    Stefan Esser
    Medical Microbiology and Immunology, 2017, 206 : 203 - 215
  • [24] Role of Proviral HIV-1 DNA Genotyping for People Living with HIV (PLWH) Who Had Low-Level Viremia While Receiving Antiretroviral Therapy
    Lv, Shiyun
    Sun, Lijun
    Li, Tongzeng
    Bai, Ruojing
    Dai, Man
    Wang, Ran
    Zhai, Yuanyi
    Hua, Wei
    Li, Aixin
    Xin, Ruolei
    Dai, Lili
    INFECTION AND DRUG RESISTANCE, 2023, 16 : 4697 - 4706
  • [25] Natural history of patients with low-level HIV viremia on antiretroviral therapy
    Lo Re, V
    Gasink, L
    Kostman, JR
    Leonard, D
    Gross, R
    AIDS PATIENT CARE AND STDS, 2004, 18 (08) : 436 - 442
  • [26] HIV Viremia and Risk of Stroke Among People Living with HIV Who Are Using Antiretroviral Therapy
    Harding, Barbara N.
    Avoundjian, Tigran
    Heckbert, Susan R.
    Whitney, Bridget M.
    Nance, Robin M.
    Ruderman, Stephanie A.
    Kalani, Rizwan
    Tirschwell, David L.
    Ho, Emily L.
    Becker, Kyra J.
    Zunt, Joseph
    Chow, Felicia
    Huffer, Andrew
    Mathews, W. Christopher
    Eron, Joseph
    Moore, Richard D.
    Marra, Christina M.
    Burkholder, Greer
    Saag, Michael S.
    Kitahata, Mari M.
    Crane, Heidi M.
    Delaney, Joseph C.
    EPIDEMIOLOGY, 2021, 32 (03) : 457 - 464
  • [27] Addressing tuberculosis in differentiated care provision for people living with HIV
    Pathmanathan, Ishani
    Pevzner, Eric
    Cavanaugh, Joseph
    Nelson, Lisa
    BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2017, 95 (01) : 3 - 3
  • [28] Assessment of palliative care needs for people living with HIV/AIDS in Rwanda
    Uwimana, J.
    Struthers, P.
    PROGRESS IN PALLIATIVE CARE, 2008, 16 (03) : 119 - 128
  • [29] Treatment outcomes of low-level viremia among adults living with HIV on dolutegravir-based first line antiretroviral therapy in Botswana
    Bareng, Ontlametse T.
    Moyo, Sikhulile
    Mudanga, Mbatshi
    Sebina, Kagiso
    Koofhethile, Catherine
    Choga, Wonderful
    Gobe, Irene
    Motswaledi, Modisa
    Maruapula, Docas
    Moraka, Natasha
    Musonda, Rosemary
    Nkomo, Joseph
    Ramaabya, Dinah
    Chebani, Tony
    Makuruetsa, Penny
    Makhema, Joseph
    Gaseitsiwe, Simani
    BMJ GLOBAL HEALTH, 2023, 8 (SUPPL_10): : A24 - A24
  • [30] Incidence of low-level viremia and its impact on virologic failure among people living with HIV who started an integrase strand transfer inhibitors: a longitudinal cohort study
    Lao, Xiaojie
    Zhang, Hanxi
    Deng, Meiju
    Li, Qun
    Xiao, Qing
    He, Lin
    Ma, Liying
    Song, Aqian
    Liang, Xuelei
    Yu, Fengting
    Zhao, Hongxin
    Zhang, Fujie
    BMC INFECTIOUS DISEASES, 2024, 24 (01)